Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study

[Cancer Management and Research](cancer-management-and-research-journal) » [Volume 14](cancer-management-and-research-archive55-v1655) Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study Authors [Zhang S](author_profile.php?id=1654738)…

Continue Reading Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
Study: Understanding The Clinical Course of MuSK-positive Myasthenia Gravis
https://pixabay.com/en/magnifier-glass-magnifying-glass-1714172/

Study: Understanding The Clinical Course of MuSK-positive Myasthenia Gravis

In order to create treatments and diagnostic methods for rare diseases, it's necessary to have a thorough understanding of said disease. A recent study aimed to do just this. Titled…

Continue Reading Study: Understanding The Clinical Course of MuSK-positive Myasthenia Gravis
MuSK-CAART for MG Earns Fast Track Designation
source: pixabay.com

MuSK-CAART for MG Earns Fast Track Designation

Currently, there are few effective therapeutic options for patients with MuSK antibody-positive myasthenia gravis (MG). A majority of those with MG have autoantibodies targeting the acetylcholine receptor. As a result, acetylcholinesterase…

Continue Reading MuSK-CAART for MG Earns Fast Track Designation

The Similarities and Differences Between Myasthenia Gravis and Multiple Sclerosis

A recent article from Healthline highlighted the similarities and differences between two neurological diseases, myasthenia gravis (MG) and multiple sclerosis (MS). Myasthenia Gravis Deriving from the Greek and Latin words…

Continue Reading The Similarities and Differences Between Myasthenia Gravis and Multiple Sclerosis
Batoclimab Receives Breakthrough Therapy Designation for Myasthenia Gravis Treatment
qimono / Pixabay

Batoclimab Receives Breakthrough Therapy Designation for Myasthenia Gravis Treatment

The China Center for Drug Evaluation (CDE) has recently granted Harbour BioMed the Breakthrough Therapy designation for batoclimab, a treatment for adults with myasthenia gravis (MG). This designation was created…

Continue Reading Batoclimab Receives Breakthrough Therapy Designation for Myasthenia Gravis Treatment